UNLIMITED TURBO SHORT - NOVO-NORDISK B | Market Closed - Borsa Italiana 16:04:59 2024-06-25 EDT | ||
| 1.78 EUR | 0.00% |
|
| Current month | -43.67% | ||
| 1 month | -42.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 1.735 | -21.85% |
| 24-06-24 | 2.22 | -2.20% |
| 24-06-21 | 2.27 | +2.71% |
| 24-06-20 | 2.21 | -5.96% |
| 24-06-19 | 2.35 | -2.89% |
Real-time Borsa Italiana
Last update June 25, 2024 at 04:04 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| P20I85 | |
| ISIN | NLBNPIT20I85 |
| Date issued | 2024-03-11 |
| Strike | 1,135 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.34 € |
|---|---|
| Lowest since issue | 1.665 € |
| Spread | 0.125 € |
| Spread % | 6.78% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
DKK
Average target price
938.1
DKK
Spread / Average Target
-8.74%
- Stock Market
- Certificates
- P20I85 Certificat
